Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market

07:40 EDT 6 Apr 2020 | Pharmaceutical Business Review

BioArdis will retain all rights to the licensed product in the rest of the world. BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC)

More From BioPortfolio on "Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market"